New York, USA, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Colorectal Cancer Clinical Trials Pipeline Analysis Featuring 125+ Key Companies by DelveInsight
Colorectal Cancer Pipeline constitutes 125+ key companies continuously working towards developing 150+ Colorectal Cancer treatment therapies, analyzes DelveInsight
DelveInsight’s 'Colorectal Cancer Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline colorectal cancer therapies in various stages of clinical development, major pharmaceutical players working to advance the pipeline space and future growth potential of the colorectal cancer pipeline domain.
Key Takeaways from the Colorectal Cancer Pipeline Report
- DelveInsight’s colorectal cancer pipeline analysis depicts a robust space with 125+ active players working to develop 150+ pipeline therapies.
- Some of the key pharmaceutical players working to develop potential colorectal cancer drug candidates to improve the colorectal cancer treatment landscape include Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, Innovative Cellular Therapeutics, Merck KGaA, Lyell Immunopharma, and others.
- Key colorectal cancer pipeline therapies in various stages of development include Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, GCC19CART, M 9140, LYL845, and others.
- In October 2022, Lyell Immunopharma announced that the US Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application to initiate a Phase 1 clinical trial for LYL845. Phase I trial to initially enroll patients with relapsed and/or refractory metastatic or locally advanced melanoma and subsequently expand into non-small cell lung cancer and colorectal cancer.
- In September 2022, Agenus announced the initiation of a global Phase II program of botensilimab, an Fc-enhanced anti-CTLA-4 that activates innate and adaptive immune responses. These trials include ACTIVATE-Colorectal, a Phase II study designed to evaluate botensilimab as monotherapy and in combination with balstilimab (anti-PD-1) for the treatment of microsatellite stable colorectal cancer.
- In September 2022, BioNTech announced that the first colorectal cancer patient had been treated with its individualized mRNA cancer vaccine BNT122 (autogene cevumeran, RO7198457) in a Phase II clinical trial.
- In August 2022, ALX Oncology initiated the Phase II clinical trial of evorpacept plus Erbitux (cetuximab) and Keytruda (pembrolizumab) in refractory microsatellite stable metastatic colorectal cancer (mCRC) patients. The combination treatment is intended for mCRC patients who have advanced following a minimum of two lines of systemic therapy.
- In August 2022, Celyad Oncology announced that the US Food and Drug Administration (FDA) lifted the clinical hold on the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial after the Company made changes to the eligibility criteria for the trial.
- In June 2022, Exelixis announced the initiation of STELLAR-303, a Phase III pivotal trial evaluating XL092 in combination with atezolizumab versus regorafenib in patients with metastatic colorectal cancer (CRC) that is not microsatellite instability-high or mismatch repair-deficient, who have progressed after or are intolerant to the standard of care therapy.
Request a sample and discover the recent advances in colorectal cancer drug trials @Colorectal Cancer Pipeline Report
The colorectal cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage colorectal cancer products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the colorectal cancer pipeline landscape.
Colorectal Cancer Overview
Colorectal cancer is cancer of the colon, rectum, or both. The rectum is the passageway between the colon and the anus. Most colorectal cancers begin as polyps, which are abnormal growths inside the colon or rectum that can turn cancerous if not removed. Colorectal cancer (cancer of the colon or rectum) is highly treatable if detected early. Even if it spreads to nearby lymph nodes, surgery followed by chemotherapy is extremely effective. The exact colorectal cancer causes are unknown, but certain risk factors, such as diet, tobacco use, and heavy alcohol consumption, are strongly linked to the disease.
Colorectal cancer symptoms may be minor or non-existent in the early stages of the disease, though some early warning signs may exist. Colorectal cancer symptoms may not appear until the disease has advanced to stage 2 or beyond. There are several tests used for colorectal cancer diagnosis. Colonoscopy and biopsy are widely used tests for colorectal cancer diagnosis.
Find out more about the disease and recent developments in colorectal cancer trials @Colorectal Cancer Medication
Colorectal Cancer Pipeline Drugs
| Drug | Company | Phase | MoA | RoA |
| XL092 | Exelixis | Phase III | Protein tyrosine kinase inhibitors; Proto oncogene protein c met inhibitors | Oral |
| Adagrasib | Mirati Therapeutics | Phase III | KRAS protein inhibitors | Oral |
| Patritumab Deruxtecan | Daiichi Sankyo Company | Phase II | DNA topoisomerase I inhibitors | Intravenous |
| Etrumadenant | Arcus Biosciences | Phase II | Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists | Oral |
| RO7198457 | Genentech | Phase II | Immunostimulants | Intravenous |
| IBI310 | Innovent Biologics | Phase II | Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; T lymphocyte stimulants | Intravenous |
| AL2846 | Advenchen Laboratories | Phase I/II | Receptor protein-tyrosine kinase antagonists | Intravenous |
| Onvansertib | Cardiff Oncology | Phase I/II | Polo-like kinase 1 inhibitors | Oral |
| CYAD-101 | Celyad | Phase I | Immunologic cytotoxicity; T lymphocyte replacements | Parenteral |
| GCC19CART | Innovative Cellular Therapeutics | Phase I | Immunologic cytotoxicity; T lymphocyte replacements | Intravenous |
| M 9140 | Merck KGaA | Phase I | Unspecified | Parenteral |
Learn more about the emerging colorectal cancer pipeline therapies @Colorectal Cancer Clinical Trials
Colorectal Cancer Therapeutics Assessment
The colorectal cancer pipeline report proffers an integral view of the colorectal cancer emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Colorectal Cancer Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration
- Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
- Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: DNA topoisomerase I inhibitors, KRAS protein inhibitors, Adenosine A2A receptor antagonists, Adenosine A2B receptor antagonists, Receptor protein-tyrosine kinase antagonists, Polo-like kinase 1 inhibitors, Immunostimulants, Axl receptor tyrosine kinase inhibitors, Protein tyrosine kinase inhibitors, Proto oncogene protein c met inhibitors, Proto-oncogene protein c-mer inhibitors, Vascular endothelial growth factor receptor antagonists
- Key Colorectal Cancer Companies: Daiichi Sankyo Company, Mirati Therapeutics, Apollomics, Treos Bio Zrt, AskAt, Effector Therapeutics, Menarini Group, ImmunityBio, Arcus Biosciences, Abraxis Bioscience, Chia Tai Tianqing Pharmaceutical Group, Aadi, LLC, BioNTech SE, Novartis, Immunovative Therapies, Transgene, Cardiff Oncology, Genentech, Sumitomo Pharma Oncology, GamaMabs Pharma, Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, Innovent Biologics, Sinomab, Yooyoung Pharmaceutical, Amal Therapeutics, Celleron Therapeutics, Merck Sharp & Dohme Corp, Isofol Medical, Surgimab, EpicentRx, Inc, Apros Therapeutics, Eisai Co., Ltd., Puma Biotechnology, G1 Therapeutics, Mologen AG, Celyad Oncology, Jiangsu HengRui Medicine, Evelo Biosciences, Sinocelltech, Moderna Therapeutics, Sichuan Kelun Pharmaceutical Research Institute, Nektar Therapeutics, MedPacto, Karyopharm Therapeutics, Gritstone Oncology, Lumicell, Inc., IDEAYA Biosciences, Cantargia AB, NextCure, Inc., Lokon Pharma AB, Chongqing Precision Biotech Co., Ltd, Bold Therapeutics, OBI Pharma, Inc, Gritstone Oncology, IGM Biosciences, Rgenix, Inc., Precision Biologics, Inc, MacroGenics, Academia Sinica, and others.
- Key Colorectal Cancer Pipeline Therapies: Patritumab Deruxtecan, Adagrasib, Geptanolimab, PolyPEPI1018, Grapiprant, eFT508, MEN1611, Aldoxorubicin Hydrochloride, Etrumadenant, AL2846, ABI-009, RO7198457, Dabrafenib, AlloStim, TG6002, Onvansertib, BLYG8824A, Napabucasin, GM102, QL1203, CPGJ602, PM060184, Donafenib, IBI310, Spartalizumab, CMAB009, YYB101, ATP128, Vicriviroc, CXD101, Arfolitixorin, SGM-101, RRx-001, APR003, E7386, Trastuzumab, Trilaciclib, MGN1703, BBI608, CYAD-101, SHR-A1811, EDP1503, SCT-I10A, KL-140, V941, NKTR-255, TEW-7197, MGD019, KPT-8602, GRT-C901, LUM015, IDE196, CAN04, NC410, LOAd703, CEA CAR-T cells, BOLD-100, OBI-833, GRT-C903, IGM-8444, RGX-202-01, NE-201, DS-8201, and others.
Dive deep into rich insights for drugs for colorectal cancer treatment, visit @Colorectal Cancer Treatment
Table of Contents
| 1. | Colorectal Cancer Pipeline Report Introduction |
| 2. | Colorectal Cancer Pipeline Report Executive Summary |
| 3. | Colorectal Cancer Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Colorectal Cancer Pipeline Therapeutics |
| 7. | Colorectal Cancer Pipeline: Late Stage Products (Phase III) |
| 7.1 | XL092: Exelixis |
| 8. | Colorectal Cancer Pipeline: Mid Stage Products (Phase II) |
| 8.1 | IBI310: Innovent Biologics |
| 9. | Colorectal Cancer Pipeline: Early Stage Products (Phase I) |
| 9.1 | GCC19CART: Innovative Cellular Therapeutics |
| 10. | Colorectal Cancer Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Colorectal Cancer Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Colorectal Cancer Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on colorectal cancer pipeline therapeutics, reach out @Colorectal Cancer Drugs
Related Reports
Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key colorectal cancer companies including Qilu Pharmaceutical, Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., PharmaMar, Suzhou Zelgen Biopharmaceuticals, among others.
Colorectal Cancer Epidemiology
Colorectal Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted colorectal cancer epidemiology in the 7MM.
Metastatic Colorectal Cancer Pipeline
Metastatic Colorectal Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic colorectal cancer companies, including Amgen, Eisai, Merck, Mologen, Celltrion, among others.
Metastatic Colorectal Cancer Market
Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic colorectal cancer companies including Amgen, Eisai, Merck, Mologen, Celltrion, among others.
Microsatellite Stable Colorectal Cancer Market
Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic colorectal cancer companies including NeoImmune Tech, Merck, Arrys Therapeutics, among others.
Microsatellite Stable Colorectal Cancer Pipeline
Microsatellite Stable Colorectal Cancer Pipeline Insight – 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic colorectal cancer companies, including NeoImmune Tech, Merck, Arrys Therapeutics, among others.
For more insights, browse through our latest blog on Metastatic Colorectal Cancer Treatment Market
Other Trending Reports
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
